Collaborating to deliver better inhalation technologies and therapies

Working together for a better future

While Senzer has the best-in-class technology for the delivery of pharmaceutical cannabinoids, we understand that innovation doesn’t happen in isolation. That’s why we allocate significant financial and corporate resources to our business development activities and strategies. These close and collaborative alliances and partnerships are the cornerstones of our commercial growth strategy.

We are always interested in meeting with potential new partners from across the world and establishing new collaborations with pharmaceutical companies which are interested in developing the best respiratory cannabinoid products and bringing them to market to enhance the lives of people living in their region. Our inhalation technologies are unique, can be manufactured at scale, and have a track record of regulatory compliance.

In-licensing

Senzer exclusively has in-licensed an international patent portfolio of 330 granted patents in the field and maintains close licensing arrangements with the holder. Senzer also holds its own intellectual property developed in-house for specific target areas and therapies.

Out-licensing

The strength and depth of our in-licensed patents and our own IP protects our unique delivery of respiratory cannabinoids. We generally choose to work with partners where we can out-licence our portfolio strategically and work with them commercially to deliver new products to patients.

Manufacturing & Distribution

In particular cases, Senzer manufactures and distributes products directly to partners that are either looking to undertake regulatory programmes with new products or new indications, or bring products to market directly through a compassionate or special use.

Unlicensed & Specials

In specific markets such as the UK, Senzer can distribute products to pharmacies under an unlicensed medicine or Specials route. These are prescription-only unlicensed medicines for patients who may benefit from cannabinoid respiratory products as part of their treatment options.

We always welcome approaches from potential new partners. Please get in touch below.